1R. Morant,J. Bernhard,R. Maibach,M. Borner,M. F. Fey,B. Thürlimann,E. Jacky,F. Trinkler,J. Bauer,G. Zulian,S. Hanselmann,C. Hürny,F. Hering. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma[J] 2000,Annals of Oncology(2):183～188
3Mendiratta P,Armstrong AJ,George DJ.Current standard and investigational approaches to the management of hormone refractory prostate cancer[J].Rev Urol,2007,9(Suppl 1):9-19.
4Newman L A, Lee C T, Parekh L P, et al. Use of the national cancer data base to develop clinical trials accrual targets that are ap- propriate for minority ethnicity patients: a report from the american college of surgeons oneology group (ACOSOG) special population committee[J]. Cancer, 2006,106(1) :188-195.
5Mendiratta P, Armstrong A J, George D J. Current standard and in vestigational approaches to the management of hormone-refractory prostate cancer[J]. Rev Urol, 2007, 9(Suppl 1) :9 19.
6Bracarda S. Chemotherapy o{ postate cancer: potential role of do- eetaxelEJ3. Tumorigenesis, 2001,87(6) : 12-14.
7Tester W, Ackler J, Tijani L, et al. Phase Ⅰ/Ⅱ study of weekly do cetaxel and vinblastine in the treatment of metastatic hormonerefractory prostate carcinoma [J]. Cancer J, 2006, 12(4) : 299-304.
8Mendiratta P, Armstrong A J, George DJ. Current standard and in- vestigational approaches to the management of hormone-refractory prostate cancer[ J]. Rev Urol,2007,9( Suppl 1 ):$9 -S19.
